DIABETES MEDICATIONS AS MONOTHERAPY OR METFORMIN - BASED COMBINATION THERAPY FOR TYPE 2 DIABETES: A SYSTEMATIC REVIEW
DOI:
https://doi.org/10.53555/nnmhs.v9i8.1810Keywords:
Blood sugar, Metformin, Monotherapy, Type 2 diabetes medicationsAbstract
Introduction: Early combination therapy may reduce glucotoxicity. This method may improve insulin sensitivity and preserve β-cell bulk and function.10 Early combination therapy with several antihypertensive agents may increase costs and patient compliance due to the number of pills, but a fixed-dose medication combination can help.
The aim: This article compared monotherapy or metformin - based combination therapy for type 2 diabetes medications.
Methods: By comparing itself to the standards set by the Preferred Reporting Items for Systematic Review and MetaAnalysis (PRISMA) 2020, this study was able to show that it met all of the requirements. So, the experts were able to make sure that the study was as up-to-date as it was possible to be. For this search approach, publications that came out between 2013 and 2023 were taken into account. Several different online reference sources, like Pubmed and SagePub, were used to do this. It was decided not to take into account review pieces, works that had already been published, or works that were only half done.
Result: In the PubMed database, the results of our search brought up 88 articles, whereas the results of our search on SagePub brought up 56 articles. The results of the search conducted for the last year of 2013 yielded a total 42 articles for PubMed and 31 articles for SagePub. In the end, we compiled a total of 11 papers, 7 of which came from PubMed and four of which came from SagePub. We included three research that met the criteria.
Conclusion: Initiation of the AHA combination of metformin and other drugs may provide better results in diabetes control. In addition, the combination of two and three drugs did not show significantly different results.
References
. International Diabetes Federation. Diabetes. Brussels: IDF; 2017.
. Evans K. Diabetic ketoacidosis: update on management. Clin Med. 2019 Sep;19(5):396–8.
. Association AD. 15. Diabetes Care in the Hospital: Standards of Medical Care in Diabetes—2019. Diabetes Care
[Internet]. 2018 Dec 7;42(Supplement_1):S173–81. Available from: https://doi.org/10.2337/dc19-S015
. American Diabetes Association. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 2016;62–9.
. Davies MJ, D’Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018 Dec;41(12):2669–701.
. Khunti S, Khunti K, Seidu S. Therapeutic inertia in type 2 diabetes: prevalence, causes, consequences and methods to overcome inertia. Ther Adv Endocrinol Metab. 2019;10:2042018819844694.
. Kaur J. A comprehensive review on metabolic syndrome. Cardiol Res Pract. 2014;2014.
. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med. 2002;137(1):25–33.
. Lalau J-D, Arnouts P, Sharif A, De Broe ME. Metformin and other antidiabetic agents in renal failure patients. Kidney Int. 2015;87(2):308–22.
. Laiteerapong N, Ham SA, Gao Y, Moffet HH, Liu JY, Huang ES, et al. The Legacy Effect in Type 2 Diabetes: Impact of Early Glycemic Control on Future Complications (The Diabetes & Aging Study). Diabetes Care. 2019 Mar;42(3):416–26.
. Cersosimo E, Johnson EL, Chovanes C, Skolnik N. Initiating therapy in patients newly diagnosed with type 2 diabetes: Combination therapy vs a stepwise approach. Diabetes Obes Metab. 2018 Mar;20(3):497–507.
. Phung OJ, Sobieraj DM, Engel SS, Rajpathak SN. Early combination therapy for the treatment of type 2 diabetes mellitus: systematic review and meta-analysis. Diabetes Obes Metab. 2014 May;16(5):410–7.
. Vuong TNL, Phung HT, Ho MT. Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial. Hum Reprod. 2015 May;30(5):1188–95.
. Lin Y-Y, Weng S-F, Hsu C-H, Huang C-L, Lin Y-P, Yeh M-C, et al. Effect of metformin monotherapy and dual or triple concomitant therapy with metformin on glycemic control and lipid profile management of patients with type 2 diabetes mellitus [Internet]. Vol. 9, Frontiers in Medicine. 2022. Available from: https://www.frontiersin.org/articles/10.3389/fmed.2022.995944
. Matthews DR, Paldánius PM, Proot P, Chiang Y, Stumvoll M, Del Prato S. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet. 2019;394(10208):1519– 29.
. Henry RR, Frias JP, Walsh B, Skare S, Hemming J, Burns C, et al. Improved glycemic control with minimal systemic metformin exposure: Effects of Metformin Delayed-Release (Metformin DR) targeting the lower bowel over 16 weeks in a randomized trial in subjects with type 2 diabetes. PLoS One. 2018;13(9):e0203946.
. Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC Guidelines on diabetes, prediabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020 Jan;41(2):255– 323.
. Cheng AYY. Canadian Diabetes Association 2013 clinical practice guidelines for the prevention and management of diabetes in Canada. Introduction. Can J diabetes. 2013 Apr;37 Suppl 1:S1-3.
. Buse JB, Wexler DJ, Tsapas A, Rossing P, Mingrone G, Mathieu C, et al. 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2020 Feb;63(2):221–8.
. Maruthur NM, Tseng E, Hutfless S, Wilson LM, Suarez-Cuervo C, Berger Z, et al. Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes: A Systematic Review and Metaanalysis. Ann Intern Med. 2016 Jun;164(11):740–51.
. Cahn A, Cefalu WT. Clinical Considerations for Use of Initial Combination Therapy in Type 2 Diabetes. Diabetes Care. 2016 Aug;39 Suppl 2(Suppl 2):S137-45.
. Cai X, Gao X, Yang W, Han X, Ji L. Efficacy and Safety of Initial Combination Therapy in Treatment-Naïve Type 2 Diabetes Patients: A Systematic Review and Meta-analysis. Diabetes Ther Res Treat Educ diabetes Relat Disord. 2018 Oct;9(5):1995–2014.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing
Ninety Nine Publication publishes articles under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This licensing allows for any use of the work, provided the original author(s) and source are credited, thereby facilitating the free exchange and use of research for the advancement of knowledge.
Detailed Licensing Terms
Attribution (BY): Users must give appropriate credit, provide a link to the license, and indicate if changes were made. Users may do so in any reasonable manner, but not in any way that suggests the licensor endorses them or their use.
No Additional Restrictions: Users may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
